A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis

Haematologica. 2019 Sep;104(9):e415-e419. doi: 10.3324/haematol.2018.207704. Epub 2019 Feb 21.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Bortezomib / pharmacology
  • Cell Line, Tumor
  • Drug Resistance, Neoplasm*
  • Female
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Homeostasis
  • Humans
  • Hydrogen Peroxide / chemistry
  • Lipids / chemistry
  • Metabolomics
  • Middle Aged
  • Mitochondria / metabolism*
  • Multiple Myeloma / drug therapy*
  • Oligopeptides / pharmacology
  • Proteasome Endopeptidase Complex / metabolism
  • Proteasome Inhibitors / pharmacology*
  • Protein Folding
  • Reactive Oxygen Species / metabolism
  • Sphingomyelins / biosynthesis*

Substances

  • Antineoplastic Agents
  • Lipids
  • Oligopeptides
  • Proteasome Inhibitors
  • Reactive Oxygen Species
  • Sphingomyelins
  • Bortezomib
  • carfilzomib
  • Hydrogen Peroxide
  • Proteasome Endopeptidase Complex